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Abstract 
Inhaled anesthetics used in hospital surgeries are typically volatile halogenated hydrocarbons. 
Very few of them are absorbed or metabolized by the patient during use, and, therefore, most of 
the exhaled gases are collected in the exhaust system and emitted directly to the environment, 
where they contribute to global warming and stratospheric ozone depletion. This research 
focuses on a capture and treatment system for the common anesthetic gases (Isoflurane, 
Sevoflurane and Desflurane) which includes the capture of these compounds in addition to their 
recovery by regeneration in a form that can possibly be re-used in hospitals or manufacture.  
The first step in this research was the development of appropriate quantification methods using a 
gas chromatograph and an FTIR instrument for accurate measurement of the concentrations in  
batch and continuous flow systems, respectively. In developing a capture system, activated 
carbon, molecular sieves, and other adsorbents were tested in different batch experiments using  
several of the most common anesthetic compounds. The activated carbon Norit A48 (with 100% 
adsorption efficency) was 1.5 to 4 times more efficient at absorbing the halothane than either the 
polyethylene (25%), the molecular sieve 4A (38%), the industrial white adsorbent (57 %), and 
the silica gel (63 %) at room temperature.  It was similar in adsorption capacity to the Activated 
Carbon RB 40M (99.8%), the Activated Carbon Vapure 410 (98.8%), the Molecular Sieve 13X 
(96 %), and the Sigma Activated Carbon (87 %). The GAC 48 (96.5 %) was 1.8 to 2 times more 
efficient at absorbing the Isoflurane than the industrial white adsorbent (41 %), and the silica gel 
(51 %) at room temperature. Isoflurane with intial volumes of 50, 100, 150 and 200 µl were 
adsorbed by GAC A48 with 98.8, 96.5, 74.5, and 64.1 % efficiency, respectively, after 120 
minutes. In addition, sevoflurane with intial volumes of 50, 100, 150 and 200 µl were captured 
By GAC A48 with 99.0, 72.6, 65.3, and 50.4 % efficiency in the same time. Therefore, GAC 
A48 was selected as the best adsorbent for capturing both Isoflurane and Sevoflurane with the 
same adsorption rate at room temperature. 
Adsorption isotherms were measured for activated carbon and a selection of different 
anesthetics. In order to account for all the factors in the adsorption process at the hospital, the 
effects of other parameters such as temperature, gas mixing, initial concentration, and humidity 
  iv 
were tested. TGA (thermal gravimetric analysis) was used to confirm that complete desorption 
was possible in the batch system.  
Before the industrial set up was tested, a flow through system with air as the carrier gas was 
designed in the laboratory to closely simulate the expected hospital emissions. Satisfactory 
results obtained in the laboratory were followed with the installation of  a tank  containing the 
best adsorbent connected to a hospital emission system. When the tank carbon bed reached  its 
saturation point after three weeks, desorption  proceeded in two steps:  “depressurization” and “ 
heated desorption”. Desorbed amounts of anesthetic in the depressurization step were negligible 
in comparison with the amounts collected in the heated desorption step in which a tank of 
activated carbon was heated while air was passed through it.  
The condensation of desorbed anesthetics was successfully performed in two stages:  the 
removal of water and the condensation of desorbed anesthetics in in a flask and a coil that were 
both  immersed in dry ice.  The temperature of the dry ice was at least -78 °C.  Analysis of the 
condensate in the second stage confirmed the capture of relatively pure sevoflurane and 
desflurane.  A white solid and a little oily liquid by-product were detected during the desorption 
process that could not be accurately identified by using available laboratory analytical methods. 
The anesthetic gas absorption results using a tank of activated carbon at the hospital illustrates 
that the optimal adsorbent could adsorb anesthetics at about 25 % of its initial weight, although 
some break-through happened before the saturation point was reached. The main 
recommendations arising from these experiments include:  Installing an online tank heating 
system to enhance the desorption of the anaesthetic gas collection system; and designing a heat 
exchanger system for effective condensation of the anesthetic gases after the desorption process. 
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1. Introduction 
1-1 Anesthetic gases 
 
Inhalation anesthetics are a form of narcotic which are usually made of simple halogenated 
hydrocarbons, paraffins or ethers that are in a liquid state at room temperature and are evaporated 
prior to inhalation. They are administered by an anesthesia mask, laryngeal mask airway or 
tracheal tubes connected to some type of vaporizer delivery system. Common anesthetics are 
Isoflurane (2,2,2-trifluoro-1-chloroethyl difluoro methyl ether), Sevoflurane (1,1,1,3,3,3-
hexafluoro-2-(fluoromethoxy)propane), Desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl 
ether) and Nitrous oxide (also known as “laughing gas”). The effect obtained from such 
halogenated hydrocarbons is normally increased by an addition of laughing gas at concentrations 
of 50-70 volume %.[1] Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) is another anesthetic 
compound that was used as anesthesia in the past but as it has some side effects it was substituted 
by the current gases. 
The ideal volatile anesthetic agent should create smooth and trustworthy induction and 
continuence of general anesthesia with minimal effects on other organ systems. Furthermore it 
should be odorless or pleasant to inhale; safe for all ages and in pregnancy; not metabolized; 
rapid in onset and offset; potent and safe for exposure to operating room staff. Additionally,it 
should be cheap to manufacture; easy to transport and store, with a long shelf life; easy to 
administer and monitor with existing equipment; stable to light, plastics, metals, rubber and soda 
lime; non-flammable and environmentally safe. None of the current chemicals in use are ideal, 
while many have some of the suitable characteristics. The full mechanism of action of volatile 
anesthetics is not fully understood. An effect of these gases is described by physical interaction 
not a chemical bond actions, although the agent may bind to a receptor with a weak interaction. 
The three common anesthetic gases (sevoflurane, desflurane and isoflurane) undergo very little 
in-vivo metabolism in clinical use. Less than 5% of these volatile anesthetics is metabolized by 
the patient.[2]  Therefore, most of the inhaled gases are exhaled and scavenged by the exhaust 
system to emit directly to the environment. 
 
  2 
Isoflurane 
 
Isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-
trifluoro-ethane) is a halogenated ether used for 
inhalational anesthesia as a substitute for the 
flammable ether and Halothane with fewer side 
effects . The application of this anesthetic gas 
recently has decreased because of a 
neurodegeneration risk [2] and replaced with two 
others Sevoflurane and Desflurane .  
Isoflurane is a clear, colorless, liquid at room temperature but vaporized easily, containing no 
additives or chemical stabilizers. Isoflurane has a mildly pungent, musty, ethereal odor. 
Isoflurane does not decompose in the presence of soda lime (at normal operating temperatures), 
and does not attack aluminum, tin, brass, iron or copper. It is completely nonflammable. It is 
usually used to maintain a state of general anesthesia that has been induced with another drug, 
such as propofal.[3] Some of its physical properties are provided in Table (1-1). 
Sevoflurane 
 
 Sevoflurane is a halogenated general inhalation 
anesthetic drug. Its chemical name is fluoromethyl 
2,2,2-trifluoro-l-(trifluoromethyl) ethyl ether, with a 
structural formula that is provided  in picture (1-2). 
Sevoflurane is non-flammable and non-explosive as 
defined by the requirements of the International 
Electrotechnical Commission 601-2-13. 
  Sevoflurane is a clear, colorless, stable liquid 
containing no additives or chemical stabilizers. 
Sevoflurane is non-pungent. It is miscible with ethanol, ether, chloroform and petroleum 
benzene, and it is slightly soluble in water. Sevoflurane is stable when stored under normal room 
lighting conditions according to instructions. In modern anesthesiology, Sevoflurane with 
Figure 1-2: The chemical structure of Sevoflurane 
 
Figure 1-1: The chemical structure of Isoflurane 
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Desflurane has been replacing Isoflurane.[4] It is often administered in a mixture of nitrous oxide 
and oxygen. The fast onset and offset, low blood/gas coefficient and low irritation to mucous 
membranes make this gas the preferred agent especialy for a surgery using a mask induction .The 
major concern related to Sevoflurane is the ability to react in the presence of strong bases such as 
carbon dioxide absorbents. All of the currently used inhalational anesthetic agents react with 
some CO2  absorbents resulting in the formation of specific compounds. Sevoflurane produces a 
vinyl ether commonly referred to as compound A. It also creates other degradation products 
under special conditions that have been identified as compound B, C, D, F, and E. Desflurane, 
ethrane, and isoflurane can generate carbon monoxide in the presence of CO2  absorbents. Any 
significant clinical issue relevant to patients from any of these inhalational agent byproducts has 
never been proven.[5]  More details about the modification of anesthetic gases is explained in (1-
5). 
Desflurane 
 
Desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl 
ether) is a nonflammable and highly fluorinated 
anesthetic gases like Sevoflurane and Isoflurane. It has  
a mixture of (R) and (S) optical isomers (two mirror 
images of a chiral molcules are called optical isomer or 
enantiomers). This anesthetic gas has a much higher 
global warming effect (discussed below) and is a 
colorless, volatile liquid below 22.8°C . It is also stable 
when stored under normal room lighting conditions 
according to manufacturer instructions. With its low solubility in blood, it has the fastest onset 
and offset in comparison with Isoflurane and Sevoflurane. Its pungency and high cost are two 
significant issues related to this modern inhaled anesthetic gas. [6] 
Its degradation reaction ocurres through persistent direct contact with soda lime that produces 
low levels of fluoroform (CHF3) and  detectable levels of carbon monoxide. The amount of 
CHF3 obtained is similar to that produced with MAC-equivalent doses of isoflurane. No 
discernible degradation occurs in the presence of strong acids. The degradation process will be 
Figure 1--3: The chemical structure of Desflurane 
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clarified in details in part (1-5).[5] 
Halothane  
 
 2-bromo-2-chloro-1,1,1-trifluoroethane (Halothane) is 
an inhalational general anesthetic gas that was replaced 
with the newer generation of anesthetic gases 
(Isoflurane, Sevoflurane and Desflurane) because of 
some undesirable side effects. The price of this 
compound is significantly cheaper than isoflurane and 
the other two, and it is more readily available for 
research purposes. However, halothane’s chemical and 
physical properties are similar to the others. Therefore, 
the preliminary experiments started with this compound 
and were then repeated with three others. Some physical properties of the three common 
anesthetics and Halothane are organized in Table (1-1): 
Table (1-1): Some Physical Properties of Isoflurane, Sevoflurane, Desflurane and Halothane [20] 
Physical properties Boiling point 
at 1atm (°C) 
Density at 20°C 
(g/cm3) 
Molcular Weight  Vapour Pressure 
(Kpa) at 20°C 
Isoflurane 48.5 1.496 184.5 31.7 
Sevoflurane 58.6 1.522 200 22.9 
Desflurane 23.5 1.465 168 88.5 
Halothane 50.2 1.868 197 32.53 
1-2 Environmental implication of Anesthetic gases: 
Waste anesthetic gas halocarbons (similar in composition to CFCs (chloro-fluoro-carbons) and 
other refrigerants) have been connected to ozone depletion and to a lesser degree, global 
warming. The halocarbons used in anesthesia (primarily halogenated methyl ethyl ethers) are 
now considered significant emission sources, as other industrial and commercial halocarbon 
emissions have been greatly reduced by legislation and other initiatives in recent years. Although  
Figure 1-4: The chemical structure of 
Halothane 
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no regulation has controlled waste anesthetic gas emissions so far, this will happen in the near 
future.  
 The Global Warming Potential GWP(20), which describes the total warming impact relative to 
CO2 over 20 years, has values for the inhaled anesthetics of: sevoflurane 349, isoflurane 1401, 
desflurane 3714 and N2O 268.[8] Although Desflurane has the best offset and onset as an 
anesthetic gas, it has the worst effect on global warming. N2O in its gaseous form, usually added 
to these gases to improve their effect, leads to more environmental damage. Figure(1-5) 
demonstrates the environmental impact of the anesthetic gases as GHG (Greenhouse  gas) 
emissions with or without N2O. 
Recently, an evaluation has been made that focuses on the accumulation of these anesthetic gases 
coming from hospitals. Worldwide yearly sales of inhaled anesthetics total in the millions of 
liters, given that a busy midsize US hospital might purchase approximately 1000 L of inhaled 
anesthetics per year. Assuming an average 4.78 metric tons of CO2 emissions/passenger car/year 
in the United States, this would be the same as about 100 to 1200 passenger car 
emissions/year/midsized hospital.[7]  
Currently, gas scavenging is the most practical engineering control for removing waste 
anesthetic gases. The effect of gas scavenging can be improved by combining this method with 
other control procedures such as dilution ventilation; although, the problem is not totally solved. 
Figure 1--5: Life cycle green-house gas (GHG) emis-sions of 
anes-thetics, including waste anes-thetic gas emis-sions of 
halo-genated drugs and nitrous oxide (N2O)[ Published May 21, 
2012 at 620 × 322 in The environmental impact of anesthetic 
gases] 
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1-3 Different Techniques for Capturing and Recovery of the Waste 
Anesthetics Gases 
 
Anesthesia delivery systems in surgical facilities (medical, dental, and veterinary) produce 
significant amounts of waste anesthetic gases. Most of these gases are not metabolized by a 
patient’s body and are collected from the patient’s exhalation by a dedicated or shared vacuum 
system. The healthcare facilities usually apply one or more centrally-located vacuum pumps to 
emit  waste gases from a large number of surrounding rooms. In addition, more air is added to 
the mixture of anesthetic gases to dilute the stream before venting to the atmosphere. 
Therefore, the exhausted stream comprises (in volume percent): 25-32 percent oxygen, 60-65 
percent nitrogen, 5-10 percent nitrous oxide, and 0.1-0.5 percent volatile halocarbons, including 
fluoro-ethers, such as isoflurane, desflurane and sevoflurane.[9] 
Various methods have been suggested so far to solve the growing problem of waste anesthetic 
gas emissions: 
In 2006, a catalyst for decomposing nitrous oxide at temperatures ranging from 200 to 600°C 
was suggested as a removal method to solve the non halogonated waste anesthetic gas issue. [10] 
In a series of patents [9,12,13], the Berry research group had developed an efficient condensation 
method to collect gases in liquid or solid  form. 
In one patent, Berry in 2006 [3] suggested that a periodic batch process that liquifies  oxygen in a 
cold fractionator be applied to selectively condense nitrous oxide and other volatile halocarbon 
gas components from waste anesthetic gases at -150 ° C. 
In a second patent[12], using a low-flow scavenging system, an intelligent waste canesthetic gas 
collection unit was used to suction flow only in the presence of waste gas and stop all flow into 
the suction manifold when no waste gas was present. This method is suitable for condensation, 
because a smaller volume of gas is cooled using the condensation temperatures. 
Further, the recovery system was changed by this group  in such a way that a compressor was 
applied to increase the waste anesthetic gas pressure make it easier to condense the anesthetic 
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gas components at higher temperatures .The method was applicable with both high-flow and 
low-flow rate scavenging systems; however, a low –flow system with an intelligent collector was 
preferable.[9] 
Another applicable method for capturing and recovering of anesthetic gases is the adsorption 
process. Limited studies have been done in this area to clarify two important key questions: 
“which adsorbent should be applied?” and “how should the adsorbent system be designed?” 
In U.S. patents 5,515,845 [13] and 5,231,980 [14], a Canadian company developed a technology 
based on the adsorption process to remove the waste anesthetic gases. In this  method,  a canister 
that contains silica zeolite was applied to selectively remove an anesthetic gas from the exhaled 
stream in the surgery room. This process lasts until the adsorbent material is saturated and the 
adsorbent replaced with a fresh one, which usualy takes a few days. 
This method was more extesively investigated in 2002 by Doyle to find the efficiency of this 
system for removing isoflurane. It was concluded that Silica zeolite was effective at completely 
removing 1% isoflurane from exhaled gases for periods of eight hours. The technology 
demonstrates promise in removing isoflurane emitted from anesthesia machine scavenging 
systems.[15] 
In another paper,  different kinds of activated carbon were investigated as adsorbents to find the 
one best suited for the adsorption and desorption processes. In this paper, only Isoflurane as an 
anesthetic gas was tested.[1] 
In a third paper, Hotta specified a process that captured the waste anesthetic gases in two steps. 
First, an adsorbing cylinder removed all anesthetic gases except nitrous oxide. Then the stream 
was passed over a catalyst layer to decompose nitrous oxide .[16] 
Most of these papers and patents only focus on old anesthetic gases and sometimes Isoflurane, 
which is currently replaced by Sevoflurane and Desflurane. In addition, there is no source that 
compares different adsorbents. 
 
 
 
 
  8 
 
1-4 Adsorption Process 
 
In a surface phenomenon,atoms, ions, or molecules from a gas, liquid, or dissolved solid adhere 
to a surface. This process is a surface phenomenon  and is different from absorption where whole  
volumes participate. In an adsorption process, two substances are involved. One is the solid or 
the liquid on which adsorption occurs and this is called the adsorbent. The second is the 
adsorbate, which is the gas or liquid or the solute from a solution which gets adsorbed on the 
surface. Regarding the nature of forces existing between adsorbate and adsorbent molecules , 
two types of adsorption occur: 
1. Physical adsorption (physisorption):  the force of attraction existing between adsorbate and 
adsorbent is Vander Waal’s force. This force is quite weak and can be reversed by heating or by 
decreasing the pressure. 
2. Chemical adsorption (chemisorption): If the force of attraction existing between adsorbate and 
adsorbent is almost the same strength as the chemical bond, the adsorption is called chemical 
adsorption. It is also known as Langmuir adsorption. This process can not be reversed easily as it 
is a strong nature of force. Various elements affecting the adsorption consist of: 
1. Nature of adsorbate and adsorbent 
2. The surface area of adsorbent 
3. Activation of adsorbent. 
4. Experimental conditions such as :temperature, pressure, etc. 
Adsorption Isotherm 
 
The isotherm depicts the equilibrium of the sorption of a material at a surface at constant 
temperature. This adsorption process is usually depicated through graphs known as an adsorption 
isotherm. It displays the amount of adsorbate on the adsorbent as a function of pressure or 
concentration at constant temperature .The amount adsorbed over the mass of the adsorbent (q) is 
a useful parameter that allows comparison of different materials. 
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 Freundlich Adsorption Isotherm 
 
In 1909, Freundlich proposed an empirical expression to signify variations of the isotherm 
adsorption . This equation is named the Freundlich Adsorption Isotherm or the Freundlich 
Adsorption equation or simply the Freundlich Isotherm. 𝑞 = 𝑘𝑝!!                    𝑒𝑞(1) 
It is also written as: 𝑞 = 𝑘𝑐!!                    𝑒𝑞(2) 
q :the mass of adsorbate on mass of the adsorbent  
p: Equilibrium  pressure  of adsorbate 
C: Equilibrium concentration of adsorbate in solution 
k and 1/n :constants depend upon adsorbent and adsorbate at particular temperature 
Experimentally it was determined that extent of adsorption varies directly with pressure until 
saturation pressure Ps is reached. Beyond that point the rate of adsorption saturates even after 
applying higher pressure. Thus the Freundlich adsorption isotherm fails at higher pressure. 
As can be observed in Figure (1-6), the value of q is rising with increasing c until it reaches a 
constant value.  
Taking the logarithms of a second equation: log 𝑞 = 𝑙𝑜𝑞𝑘 + 1𝑛 log 𝑐                    𝑒𝑞(3) 
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 The log q is charted against log c and is a 
straight line in the following diagram. The 
slope shows 1/n and the value of the intercept 
presents log k. If the graph of log x/m against 
log p follows a straight line, it can be 
concluded that the freundlich adsorption 
isotherm fits this system. 
Langmuir Adsorption Isotherm 
 
In 1916 Langmuir suggested another 
adsorption isotherm known as the Langmuir 
adsorption isotherm. It was assumed in this 
theory that a dynamic equilibrium exists 
between adsorbed gaseous molecules and the 
free gaseous molecules. 
Based on his theory, the Langmuir Equation 
describes a relationship between the number 
of active sites in the surface that participate in 
the adsorption and pressure. θ = 𝐾𝑃1+ 𝐾𝑝                     𝑒𝑞(4) 
θ :the number of sites of the surface which are covered with adsorbate molecules  
P :represents pressure  
K : the equilibrium constant for distribution of adsorbate between the surface and the adsorbate 
phase .  
This theory is applicable for low pressure as is the Freundlich isotherm. 
At lower pressure, KP is so small that factor (1+KP) can almost be counted as zero. Therefore,  
the Langmuir equation is converted to 𝜃   =   𝐾𝑃                      𝑒𝑞(5)  
c 
q 
Log c 
Log q 
Figure 1-6:the Freundlich Adsorption Isotherm showing top 
(the amount adsorbed, q , as a function of equilibrium 
concentration in the solution) bottom(the logarithm amount 
adsorbed, q , as a logarithm function of equilibrium 
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At high pressure KP is so large, that 
factor (1+KP) in is nearly equal to KP. 
So the Langmuir equation is changed to:  
θ = 𝐾𝑃𝐾𝑃 = 1                  𝐸𝑞(6) 
BET Adsorption Isotherm 
 
BET Theory, discovered by Brunauer, 
Emmett and Teller, is based on a 
multilayer formation that can be applied 
to the physical adsorption phenomena. 
 The Langmuir Adsorption Isotherm is 
based on the theory that the monolayer 
only happens in low pressure. In this 
condition, gaseous molecules would 
possess high thermal energy and high 
escape velocity. Therefore, the number 
of gaseous molecules near the surface of 
adsorbent would be limited. 
In both high pressure and low 
temperature, multilayer adsorption 
happens where more adsorbent 
molecules would be accessible per unit 
surface area as the thermal energy of 
gaseous molecules fall. The BET equation is given as 
𝑉!"!#$ = 𝑉!"#"𝐶(𝑃𝑃!)(1− 𝑝𝑃!)(1+ 𝑐 𝑝𝑃! − 𝑝𝑃!)                     𝑒𝑞(7) 𝑉!"#": adsorbed volume of adsorbate at high pressure conditions to cover the surface with a 
unilayer of gaseous molecules 
Figure 1-7: :Calculated isotherms by the Langmuir, Freundlich, 
and BET equations with the experimental data for CFC-115:   (a) 
▪, experimental value at 298 K; , Langmuir eq (298 K); , 
Freundlich eq (298 K); , experimental value at 318 K; ·  ·  ·, 
Langmuir eq (318 K); ·  ·  ·, Freundlich eq (318 K); , 
experimental value at 338 K; ·  ·  ·, Langmuir eq (338 K); ·  ·  ·, 
Freundlich eq (338 K); □, experimental value at 358 K; 
Langmuir eq (358 K); Freundlich eq (358 K). (b) , BET eq 
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P :The equilibrium pressure of adsorbates at the temperature of adsorption 𝑃!: The Saturation pressure of adsorbates at the temperature of adsorption 
C: BET Constant 
The BET method is extensively used in surface science for the calculation of surface area of 
solids by physical adsorption of gas molecules.[17] ,[18] 
There is no published study about the adsorption isotherm of the three anesthetic gases of interest  
on activated carbon or similar adsorbents.The equiblium adsorption of CFC(CFC-115, 
CF
3
CF
2
Cl), which has a similar chemical structure to the anesthetic gases, on activated carbon 
was studied in 2003. Results were fitted with mathematical relevant models using Langmuir, 
Freundlich, and BET equations. Figure (1-7-a) shows the calculated isotherms of charcoal for 
CFC-115 by the Langmuir and Freundlich equations.  
Figure( 1-7-b) displays the BET equations and the experimental data at different temperatures. 
The amount of CFC-115 adsorbed increases with increasing pressure to a maximum. In very low 
pressure and over 26.6 kpa , there is a good fit between the experimental data and the Longmuir 
graph. Differences between the Freundlich equation and experimental data increase with rising 
pressure. The BET equation has the best fit with experimental data over the all tested 
temperatures. The BET constant was calculated in this paper too.[19] 
 1-5 The anesthetic gas degradation: 
New general anaesthetics consisting  of Sevoflurane, isoflurane and  desflurane have 
successfully replaced the previous generation agents. Their suitable physicochemical 
characteristics , such as gas-blood partition coefficients, rapid onset of anaesthesia and quicker 
recovery, lower doses and better control of the patient’s condition make them relevant in the 
medical industry . To the contrary, their chemical structure causes several issues that should be 
noted in the application of theses gases. Studies have been done about the degradation of 
anesthetics that were published both in medical and chemical papers. The knowledge of how to 
apply and store these compounds and how to prevent uncontrollable degradation is extremely 
important;  especialy since these three different anesthetics are currently available.  
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From the chemical point-of-view, the carbon-fluorine bond, C-F, is unique. With respect to 
differences in the electronegativity of elements, the electron cloud of the bond creates a dipole 
with negative charge on the fluorine atom and positive charge on the carbon atom. A similar 
polarization is observed in carbon-oxygen (C-O) bonds. The formation of partial charges is the 
reason for the reactivity. Each site may be the center 
of reactions leading to molecular breakdown and 
formation of new, unfavorable or even toxic 
compounds. Sevoflurane is more sensitive, as the 
monofluormethyl group is susceptible to the attack 
of Lewis acids . Sevoflurane produces a variety of 
degradation products such as compound A 
[fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl 
ether] also called PIFE (pentafluoroisopropenyl 
fluoromethyl ether) and Compound B [1,1,1,3,3-
pentafluoro-2-(fluoromethoxy)-3-methoxypropane] 
also called PMFE (pentafluoromethoxy isopropyl 
fluoromethyl ether) on contact with a carbon 
dioxide adsorbent such as the soda lime. Different 
factors effect the degradation products quality and 
quantity such as temperature, flow rate etc.[21]  
In 1996, it was reported that Sevoflurane was not consistently stable and could be degraded by 
Lewis acids. A Lewis acid, such as FeCl3, Fe2O3and BF3, is a metal-containing molecule that can 
produce a covalent bond by accepting an unshared pair of electrons. Lewis acids react with 
sevoflurane and produce hydrogen fluoride and several other products. These compounds might 
be found in different quantities adhered to the components of the anesthesia machine, vaporizer, 
circuit, shipping and/or storage containers. There is a limited amount of  information about 
degradation products and their hazardous effects. For example fifty parts per million (ppm) of 
hydrogen fluoride exposure for 1 hour will cause serious adverse effects such as eye and skin 
irritation, a burning sensation, respiratory tract irritation (coughing, laryngitis, bronchospasm), 
respiratory tract injury (pulmonaryedema, respiratory failure, pulmonary fibrosis), achycardia, 
and hypertension. Hydrogen fluoride etches glass containers releasing aluminum oxides, which 
Figure 1- 8: Sevoflurane degradation products[21] 
  14 
are Lewis acids and a natural component of glass. This can start a self-perpetuating cycle of 
reactions. Fortunately, any hydrogen fluoride and silicon tetrafluoride produced (if the reaction 
happens in the glass container) are highly pungent gases with characteristic smells, and can be 
easily recognized. Hydrogen fluoride is detectable by smell at concentrations 100-fold lower 
than toxic levels. The contaminated sevoflurane was first identified in such a way in 1986. The 
Abbott Lab. company, the only manufacturer of sevoflurane that year, added water (up to 300-
1000 ppm) to block the formation of a Lewis acid and replaced glass containers with plastic ones 
(polyethylene naphthalate). At present, sevoflurane is produced with different water content and 
packaging. The plastic or aluminium-lined containers are produced by two companies: 
                                  Table (1-2): Comparison of preparations containing Sevoflurane [5] 
Producer Abbot Lab. Baxter 
Name Sevorane/Ultane Sevoflurane 
Purity More than 99.99% More than 99.99% 
Water Content 330 ppm 130 ppm 
Container PEN(Polyethylene Naphthalate) Aluminium Lined with Phenolic resin 
 
The chemical structure of sevoflurane is similar to diethyl ether and haloform (chloroform, 
fluoroform), therefore it acts as an organic solvent. It may cause local weakness or damage to 
organic polymers, such as polyethylene naphthalate or phenolic resin. In a inappropriate packing 
and storage conditions, some part of the content may evaporate. This was the issue with use of  a 
series of Ultane containers .In addition, in a plastic container some additives may act as potential 
Lewis acids and cause degradation. Therefore, the containers of this agent were selected 
specifically by the two manufactures to prevent any degradation issues (Table (1-2). 
Another problem regarding the new generation anaesthetics is their instability in the precense of 
CO2 absorbents used in anaesthetic machines . This effect was discovered when halothane was 
used in the closed circuit with a CO2 absorbent and extensive amounts of toxic products of 
degradation formed. Isoflurane and desflurane break down only to CO while sevoflurane 
degrades to various products when in contact with soda lime or other adsorbents that have an OH 
group . 
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In a closed anesthesia circuit,  different kinds of degradation products can be formed where the 
quality and quantity of them depend mainly on temperature and moisture of the absorbent . 
Moisture less than 15% apparently increases the capacity of the adsorbent to degerade the 
anesthetic . As the majority of reactions happening in the absorbent are exothermal, heating the 
absorber increases the degree of degradation of the anaesthetic , which, in turn, raises the 
temperature and decreases moisture (flow of warm, dry gas dries the absorber). This problem is 
more serious in a low flow system as the adsorbent temperature is increased more 
rapidly.[22,23,24,25] 
Researches have demonstrated that active sodium and potassium hydroxides enhance the 
degradation of anaesthetics .For other absorbents, which do not contain hydroxides, degeradation 
issues have not been reported.[5] 
The other point that should be noted with respect to safely applying modern inhaled anaesthetics 
is proper equipment. Suitable safety and control may be provided only in a unit with trained 
personnel and appropriate devices. Incorrect equipment may cause serious problems; there have 
been cases when the use of improper vaporizers damaged the anaesthetic machines .[5] 
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1-6 Objective of the Current Research  
 
Regarding the importance of the waste anesthetic gases problem and shortage of studies in this 
area, the objects of this project,therefore, was planned as such 
1- Determining accurate methods for measuring anesthetic gas quantity in both batch and 
continuous experiments 
2- Designing batch experiments to compare the adsorption capacity of different adsorbents 
with the new anesthetic gases (Isoflurane, Sevoflurane and Desflurane) 
3- Obtaining the isotherm of three agents on the best adsorbent and investigating 
experimental condition effects on the adsorption process 
4- Preparing in the laboratory a column of adsorbent to do a pre-test before industrial set up 
of the adsorbent container 
5- Setting and monitoring the industrial system to determine how well the system performs 
and to identify any opportunities for improvements  
6- Precisely analyzing the desorption process in two steps of the depressurizing and the 
heating desorption to find the best condition for performance of this process through 
testing different parameters such as temperature, flow rate etc. 
7- Designing and developing an effective cryogenic condensation system for recovery of the 
adsorbed gases and testing the purity of the captured gases 
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2.Experiments and Results 
2-1 The Calibration of Gas Chromatography (GC)  
The composition of anaesthetic gases (Halothane, Isoflurane, Sevoflurane and Desflurane) 
during experiments were analyzed throgh GC (HP5890 Series II) equipped with a split/splitless 
injector, a flame ionization detector (FID) and an electron capture detector (ECD) with a 30 m by 
0.53 mm RTX502.2 column (Restek, Pennsylvania). Data acquisition involved a starting oven 
temperature of 50oC followed by a ramp temperature rate of 2 oC/min to a final temperature  of 
60 oC . The first step was to set an appropriate method and calibration curve for this instrument to 
measure the composition parameters. 
Halothane Calibration Data 
To obtain a calibration curve which demonstrates the relationship between the concentration of 
sample and the GC peak area, 1 µl of Halothane was injected into a standard glass bulb with a 
volume of 2000 ml, then after half an hour of mixing at room temperature three different 
volumes from the bulb were collected and injected into the GC. This procedure was repeated for 
60 µl of Halothane . The results are summarized in Table(2-1) and Figure(2-1): 
                                                Table (2-1): The Gas Chromatography Calibration Data for Halothane 
Injected 1 µl  Halothane to Standard bulb Injected 60 µl  Halothane to Standard bulb 
Volume(ml) Amount(ng) ECD Area FID Area Volume(ml) Amount(ng) ECD Area 
FID 
Area 
100 93.6 3008 98393 100 5616 119285 2969980 
300 280.8 8439 224715 300 16848 285626 6816550 
500 468 16600 400583 500 28080 6.33E+05 1.31E+07 
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                                          Figure 2-1: Halothane Gas Chromatography calibration Curve with FID 
 
 
The electron capture detector (ECD) is generally used for detecting electron-dense compounds 
(high electronegativity) such as halogenated compounds in gas chromatography and can be 10 to 
1000 times more sensitive to these types of compounds than FID. The ECD is more sensitive to 
compounds containing chlorine than those having only fluorine. Isoflurane, with one chlorine, 
was the only compound of the three anesthetic gases studied that was detected by the ECD. 
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Figure 2-2: Halothane Gas Chromatography calibration Curve with ECD 
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However, the ECD was only used briefly for isoflurane in the laboratory when studying this 
compound.  This method was applicable only with a very dilute gas sample where the ECD 
response was within the range of 27,0571 to 250,380 area counts. For most of the experiments,  
the FID detector was used for the quantification of the anesthetic gases. 
Isoflurane and Sevoflurane Calibration Curves 
For the calibration of Isoflurane and Sevoflurane, 10 µl of each anaesthetic in  liquid form was 
injected into the standards bulb containing nitrogen and the mixture was stirrred for half an hour 
at room temperature.  For calibration of Desflurane, 100 µl of a 1% (v/v in air) was injected to 
the standard bulb contaning nitrogen. Various volumes from the mixtures were injected into the 
GC to prepare calibration curves. As explained before, only the FID method was selected for 
detection of these gases. Standard curves were prepared with ranges of 380 to 22800 ng, 374 to 
22440 ng, and 90 to 18940 ng, respectively. The individual peaks were sufficiently separated for 
identification and quantification with retention of approximately 0.722, 0.677 and 0.651 min, 
respectively. 
                        Table (2-2): The Gas Chromatography Calibration Data for Isoflurane, Sevoflurane and Desflurane 
Inject 10 µl  Isoflurane and 10 µl  Sevoflurane to standards bulb 
Volume(µl ) Sevoflurane 
Amount(ng) 
Isoflurane 
Amount(ng) 
Sevoflurane 
FID Area 
Isoflurane 
FID Area 
50 374 380 14490 8935 
100 748 760 28091 18436 
200 1496 1520 49817 31854 
300 2244 2280 78560 50401 
500 3740 3800 120055 78070 
Inject 60 µl  Isoflurane and 60 Sevoflurane to standards bulb 
50 2244 2280 61356 38682 
100 4488 4560 278536 177400 
200 8976 9120 395699 251261 
300 13464 13680 723410 461620 
500 22440 22800 61356 38682 
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Desflurane amount (ng) Desflurane FID area 
90 633 
180 1171 
11361 65869 
18937 133010 
 
 
 
Figure 2-4: Desflurane Gas Chromatography calibration Curve with FID 
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Figure 2-3: Isoflurane  and  Sevoflurane Gas Chromatography calibration Curve with FID 
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Therefore, with regards to different retention times for Isoflurane, Sevoflurane and Halothane, 
their concentration can be easily monitored by the GC in both mixed or separate samples. 
 
2-2 Adsorbent Selection  
 
 
 
The experiments were started with the old anesthetic “Halothane” that is significantly cheaper 
than the three more modern agents (Isoflurane, Sevoflurane and Desflurane). The price was not 
the only reason for selection of this compound (around $1.3 per ml of Halothane in comparison 
to $313 per ml of Isoflurane with respect to Sigma Aldrich supplier price ), the similar physical 
and chemical characteristics of this anesthetic compared to the other three, especially Isoflurane, 
created a very good source for initiating different tests (more details were explained in Section 
(1-1)). 
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Figure 2-5: The Concentration of the Halothane in the Bulb with different adsorbents over 
time 
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To find the best adsorbent, the adsorption of Halothane on different relevant adsorbents was 
tested (Figure 2-5).  An initial volume of Halothane (50 µl) was injected into a glass bulb 
(volume 250 ml) which contained a known weight of adsorbent. Then, the concentration of 
Halothane in the bulb was measured by removing a 500 µl gas sample for GC analysis over time. 
The same experiments were repeated with Isoflurane. The results are shown in Table (2-3).  As 
can be observed in Figure 2-5 and Table 2-3, the GAC 48 (100%) was 1.5 to 4 times more 
efficient at absorbing the halothane than either the polyethylene (25%), the molecular sieve 4A 
(38%), the Industrial white sample (57%), and the silica gel (63%) at room temperature.  It was 
similar in adsorption capacity to the Activated Carbon(RB 40M, 99.8%), the Activated Carbon 
Vapure 410 (98.8%), the Molecular Sieve 13X (96%), and the Sigma Activated Carbon (87%).  
                        Table (2-3): The adsorption properties of relevant adsorbent on Halothane and Isoflurane 
Adsorbent Name 
Injec
ted 
Gas 
volu
me 
Anaesthetic 
Gas 
Name 
Adsorbent 
weight 
(mg) 
Gas 
Concentration 
at First 
(ng/ml) 
Gas 
Concentration  
at Equilibrium 
(ng/ml) 
Adsorbed 
Anaesthetic 
gas% 
Industrial white sample* 100 Isoflurane 259 598000 352000 41 
Silica Gel 100 Isoflurane 262 598000 290000 51 
Industrial white sample* 50 Halothane 257 374000 156000 57 
Silica Gel 50 Halothane 294 374000 137000 63 
Activated Carbon(GAC 48) 100 Isoflurane 294 374000 137000 96.5 
Activated Carbon(GAC 48) 50 Halothane 257 374000 
Too low to 
calculate 
100 
Activated Carbon(Sigma) 50 Halothane 259 598000 20900 87 
Activated Carbon(RB 40M) 50 Halothane 254 3.74e5 700 99.8 
Activated Carbon(vapure 410) 50 Halothane 257 370000 
Too low to 
calculate 
98.8 
Molecular Sieve 13x 50 Halothane 255 374000 46500 96 
Molecular Sieve 4A 50 Halothane 254 374000 700 38 
Poly Ethylene 50 Halothane 252 374000 4200 25 
 
*provided by Class 1 as a possible zeolite type adsorbent 
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Activated Carbon Norit GAC 48 M-1869 (GAC A48),  as the best adsorbant, demonstrated 
adsorption efficiencies of 100% with an initial volume of 50 µl of halothane and 96.5% with an 
initial volume of 100 µl of  Isoflurane. As can be observed in Figure (2-6) and Table (2-3), the 
GAC 48 (96.5%) was 1.8 to 2 times more efficient at absorbing the Isoflurane than the Industrial 
white sample (41%), and the silica gel (51%) at room temperature.In addition, this particular 
activated carbon (A48) adsorbed most of the Isoflurane gas molcules in less than 10 minutes of 
the experiment. Therefore, this adsorbant was significantly more efficient in capturing the 
anaesthetic gases compared to the other adsorbents tested. In addition, between the different 
kinds of activated carbon, GAC A48 exhibited the better adsorption at different initial 
concentrations.  The white adsorbent provided by Class 1 Inc., initially used as the adsorbent in a 
small canister in surgery rooms, was demonstrated to have only half the adsorption capacity of 
the GAC A48 (Table 2-3). More experiments were completed to investigate the effect of 
different factors on the adsorption of activated carbon using GAC A48.  
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Figure 2-6: The Concentration of Isoflurane in the bulb with adsorbent over time 
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2-3 The effect of initial composition of anesthetic gas on the adsorption 
process 
Various initial volumes of halothane were injected into a bulb (250 ml) which contained GAC 
A48 (with a weight around 255 mg). The concentrations, over a 2-hour period, were measured 
using the GC. The results are organized in the Table (2-4) and Figure (2-7): 
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2 6.68E4 82.16 5.59E5 25.37 7.17E5 35.98 1.10E6 18.52 --- --- ---- ---- 
10 3.85E3 98.97 2.77E5 63.02 4.14E5 63.04 9.41E5 30.30 9.70E5 34.90 1.22E6 26.06 
30 739 99.80 1.62E5 78.37 3.42E5 69.46 6.49E5 51.93 7.95E5 46.64 1.13E6 31.52 
60 - - 1.43E5 80.91 3.14E5 71.96 3.64E5 73.04 7.45E5 50.00 1.08E6 34.55 
120 - - 8.76E4 88.30 2.27E5 79.73 3.35E5 75.19 7.40E5 50.34 1.00E6 39.39 
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Figure 2-7: The Concentration of Halothane with different initial injected volumes over time 
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The same experiments were repeated for isoflurane and sevoflurane. The results are provided in 
Table(2-5), Table(2-6), Figure(2-8) and Figure(2-9): 
 
 
                         
 
 
 
 
 
 
 
 
Table (2-5) The Concentration of  Isoflurane in the bulb with different initial injected volumes 
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Figure 2-8 The Concentration of Isoflurane in the bulb with different initial injected volumes 
over time 
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Table (2-6): Concentration of  Sevoflurane in the bulb with different initial injected volumes 
 
 
 
 
 
 
 
 
 
 
 
 
It can be observed in Table(2-5), Table(2-6), Figure(2-8) and Figure(2-9), Isoflurane  with intial 
volumes of 50, 100, 150 and 200 µl were adsorbed with 98.8, 96.5, 74.5, and 64.1% efficiency, 
respectively, after 120 minutes. In addition, sevoflurane with intial volumes of 50, 100, 150 and 
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Figure 2-9: The Concentration of Sevoflurane in the bulb with different initial injected 
volumes over time 
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200 µl were captured with 99.0, 72.6, 65.3, and 50.4 % efficiency in the same time. Therefore, 
both gases had approximately the same adsorption rate within 30 minutes. 
2-4 Mixtures of Isoflurane and Sevoflurane 
 
The other factor that was thought to possibly affect the adsorption process was competition of 
the Isoflurane and Sevoflurane molecules  on the active sites of adsorbent in a mixture of both 
gases. The adsorption of diverse mixtures of these two anaesthetic gases with more, less, and 
equal percentages of Isoflurane was tested. The results are shown Figure(2-10), (2-11) and (2-
12): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10: The Concentration of  Isoflurane and Sevoflurane in the mixture of 50 µl of 
Isoflurane plus 150 µl of Sevoflurane in the bulb with the activated carbon A48 over time 
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Figure 2-12: The Concentration of Isoflurane and Sevoflurane in the mixture of 150 µl of 
Isoflurane plus 50 µl of Sevoflurane in the bulb with the activated carbon A48 over time 
Figure 2-11: The Concentration of Isoflurane and Sevoflurane in the mixture of 100 µl of 
Isoflurane plus 100	  µl of Sevoflurane in the bulb with the activated carbon A48 over time 
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It was obvious that in a mixture of gases there was no significant competition effects for the 
adsorption on the activated carbon. Therefore, based on an initial composition, gas molecules 
occupied the activated carbon sites until an equilibrium was reached. 
Table (2-7): The isoflurane and sevoflurane concentrations in the bulb with activated carbon A48 in different mixtures of 
them 
Inject 150 µl  Sevoflurane and 50 µl  Isoflurane  to bulb with 257 mg GAC 
Time(min) Sevoflurane 
Concentration(ng/ml) 
Isoflurane 
Concentration(ng/ml) 
Total 
Concentration(ng/ml) 
0 910200 299200 1209400 
2 3.51E+05 1.61E+05 5.13E+05 
13 3.03E+05 1.59E+05 4.62E+05 
30 2.30E+05 1.14E+05 3.45E+05 
90 2.33E+05 1.14E+05 3.47E+05 
120 2.58E+05 1.39E+05 4.24E+05 
Inject 50 µl  Sevoflurane and 150 µl  Isoflurane  to bulb with 258.5  mg GAC 
Time(min) Sevoflurane 
Concentration(ng/ml) 
Isoflurane 
Concentration(ng/ml) 
Total 
Concentration(ng/ml) 
0 303400 897600 1201000 
2 2.46E+05 4.90E+05 7.36E+05 
10 1.37E+05 2.86E+05 4.23E+05 
30 1.45E+05 2.94E+05 4.39E+05 
68 1.20E+05 2.49E+05 3.69E+05 
90 1.15E+05 2.39E+05 3.55E+05 
120 1.19E+05 2.45E+05 3.65E+05 
Inject 100 µl  Sevoflurane and 100 µl  Isoflurane  to bulb with 255 mg GAC 
Time(min) Sevoflurane 
Concentration(ng/ml) 
Isoflurane 
Concentration(ng/ml) 
Total 
Concentration(ng/ml) 
0 606800 598400 1205200 
2 2.57E+05 2.04E+05 4.61E+05 
12 2.39E+05 1.78E+05 4.17E+05 
30 1.87E+05 1.39E+05 3.26E+05 
64 1.95E+05 1.44E+05 3.40E+05 
90 1.72E+05 1.26E+05 2.98E+05 
120 1.86E+05 1.37E+05 3.24E+05 
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2-5 The effect of temperature on the adsorption process 
 
The initial volumes of 100, 150 and 200 µl of halothane were selected to investigate the effect of 
temperature on the Gac A 48 adsorption. Each adsorption process was performed at three 
temperatures 23, 35 and 50°C that expected to operate at the planned hospital emission 
system.(Grand River Hospital) 
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Figure 2-13: The Concentration of Halothane in the bulb with the activated carbon A48 at 
different temperature over time with the 100 µl initial injected volume 
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Figure 2-14: The Concentration of Halothane in the bulb with the activated carbon A48 at 
different temperature over time with the 150	  µl initial injected volume 
Figure 2-15: The Concentration of Halothane in the bulb with the activated carbon A48 at 
different temperature over time with the 200	  µl initial injected volume 
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Table (2-8): Concentration of Halothane in the bulb with the activated carbon A48 at different temperature 
 
The results demonstrated that, within experimental error, there was no detectable effect of 
temperature on the adsorption over the range of 23 to 50°C, which is same  temperature used for 
the adsorption process in a tank of adsorbent in a hospital emission system. 
Inject 100 µl  halothane to bulb with GAC A48 
Time(min) Concentration in 
23C(ng/ml) 
Concentration in 
35C(ng/ml) 
Concentration in 
50C(ng/ml) 
0 748800 748800 748800 
2 559355 4.58E+05 4.87E+05 
10 277361 1.43E+05 2.24E+05 
30 161890 1.40E+05 1.16E+05 
60 143013 2.96E+04 1.21E+05 
120 87600 1.28E+05 9.51E+04 
Inject 150 µl  halothane to bulb with GAC A48 
Time(min) Concentration in 
23C(ng/ml) 
Concentration in 
35C(ng/ml) 
Concentration in 
50C(ng/ml) 
0 1123200 1123200 1123200 
2 717357 6.52E+05 6.88E+05 
16 414549 3.41E+05 4.98E+05 
30 342765 3.09E+05 4.12E+05 
60 313614 3.33E+05 3.77E+05 
120 2.28E+05 2.84E+05 3.72E+05 
Inject 200 µl  halothane to bulb with GAC A48 
Time(min) Concentration in 
23C(ng/ml) 
Concentration in 
35C(ng/ml) 
Concentration in 
50C(ng/ml) 
0 1497600 1497600 1497600 
2 1.62E+06 8.67E+05 8.23E+05 
10 9.70E+05 8.18E+05 6.50E+05 
30 7.95E+05 2.35E+05 5.89E+05 
60 6.66E+05 3.79E+05 5.76E+05 
120 5.46E+05 3.26E+05 5.86E+05 
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2-6 The Isotherm of adsorption 
 
The process of adsorption is usually studied through the adsorption isotherm. It is the graph or 
equation comparing the amounts of adsorbent at equilibrium (C∞(ng/ml)) with the mass of 
species adsorbed over the mass of adsorbent (q) at constant temperature.  
Container Isotherm 
Different volumes of Halothane were injected into the 250 ml bulb without any adsorbent to 
observe the amount of halogenated compound that was adsorbed by a container walls. The 
results for the isotherm of Halothane on the glass container are shown as follows: 
Table (2-9): Different parameters for calculating the adsorption isotherm of Halothane on the glass container 
Halothane 
volume(µl ) 
C0(ng/ml) 
 
C∞(ng/ml) 
 
W(container 
weight) (gr) 
q(ng/ng) 
 
50 374400 344020 131 5.79771E-05 
100 748800 503347 131 0.000468422 
150 1123200 734490 131 0.000741813 
200 1497600 1102170 131 0.000754637 
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Figure 2-16: Masses of Halothane adsorbed over the glass container (q) based on amount of   
Halothane at equilibrium (C∞(ng/ml))at room temperature 
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The results demonstrate that the amount of adsorbed halothane by the container walls was very 
low in comparison to the amount of gas adsorbed to the activated carbon, i.e. the container did 
not have any special effect on the adsorption process. In fact, since the container q was 1000 
times lower than the adsorbent q, it was neglected in the isotherm calculation . 
The Anesthetics Isotherm: 
 
The isotherms of Halothane, Isoflurane and Sevoflurane on the activated carbon A48 are pictured 
below:  
Table (2-10): Different parameters for calculating the adsorption isotherm of Halothane on the activated carbon A48 
Halothane volume(µl ) C0(ng/ml) 
 
C∞(ng/ml) 
 
W(activated carbon 
weight(ng) 
 
q(ng/ng) 
 
100 748800 87600 2.53E+08 6.53E-01 
150 1123200 227750 2.57E+08 8.71E-01 
180 1347840 3.35E+05 2.56E+08 9.89E-01 
200 1497600 5.46E+05 2.57E+08 9.26E-01 
220 1647360 6.45E+05 2.54E+08 9.87E-01 
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Figure 2-17: Masses of Halothane adsorbed over the activated carbon A48  (q) based on 
amount of Halothane at equilibrium (C∞(ng/ml))at room temperature 
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Freundlich:   q = 0.868 C^0.196   where q: ng/ng  C: ng/ml 
 
Table (2-11): Different parameters for calculating the adsorption isotherm of Isoflurane on the activated carbon A48 
Isoflurane 
volume(µl ) 
C0(ng/ml) 
 
C∞(ng/ml) 
 
W(activated carbon 
weight(ng) 
 
q(ng/ng) 
 
90 538560 4.58E+04 2.58E+08 4.77E-01 
100 598400 6.73E+04 2.57E+08 5.17E-01 
120 718080 1.82E+05 2.55E+08 5.25E-01 
150 897600 3.20E+05 2.57E+08 5.63E-01 
170 1017280 3.38E+05 2.55E+08 6.66E-01 
190 1136960 4.47E+05 2.57E+08 6.70E-01 
 
Figure 2-18: Log q (ng/ng)over log (C∞(ng/ml))at room temperature for Halothane on the 
activated carbon A48 
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Freundlich:   q = -4E+6 C^2E+6   where q: ng/ng  C: ng/ml 
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Figure 2-19: Masses of Isoflurane adsorbed over the activated carbon A48 (q) based on 
the amounts of Isoflurane at equilibrium (C∞(ng/ml))at room temperature 
Figure 2-20: Log q (ng/ng) over log (C∞(ng/ml))at room temperature for Isoflurane on The 
activated carbon A48 
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Table (2-12): Different parameters for calculating the adsorption isotherm of Sevoflurane on the activated carbon A48 
Isoflurane 
volume(µl ) 
C0(ng/ml) 
 
C∞(ng/ml) 
 
W(activated carbon 
weight(ng) 
 
q(ng/ng) 
 
90 546120 7.20E+04 2.59E+08 4.58E-01 
100 606800 1.25E+05 2.56E+08 4.71E-01 
120 728160 2.23E+05 2.51E+08 5.05E-01 
150 910200 2.94E+05 2.58E+08 5.97E-01 
170 1031560 4.12E+05 2.55E+08 6.07E-01 
190 1152920 5.73E+05 2.56E+08 5.66E-01 
 
 
Figure 2-21: Masses of Sevoflurane adsorbed over the activated carbon A48  (q) based on  
                          the amounts of Sevoflurane at equilibrium (C∞(ng/ml))at room temperature 
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Freundlich:   q = -4.1762 C^5.5273   where q: ng/100ng C: ng/ml 
 
In all three graphs the quantity of adsorbed gas on the activated carbon increased until it reached 
a constant value. As these concentrations are relatively low and do not cover a very wide range, 
the saturation behavior that is reperesented by the Langmuir isotherm was not expected to be 
present. Therefore, the Freundlich isotherm was assumed to be the best theory for explaining the 
adsorption behavior of the anesthetics on the activated carbon A48. The curves in Figures (2-18), 
(2-20) and (2-22) were used to find the Freundlich equation constants (k and n in equation 
 ). With regards to the  value, the K and n were measured with satisfactory accuracy 
for the purposes of comparison and preliminary design. Although Isoflurane and sevoflurane 
have some similarity in their chemical and physical properties, their K and n constants were 
found to be significantly different.   
2-7 Desorption Process In Batch System 
TGA (Thermogravimetric analysis) test 
 
The desorption amount of the gases from these samples was monitored by TGA 
(Thermogravimetric analysis).  To quantify the degree of desorption, all samples of GAC A48 
Figure 2-22: Log q (ng/ng)over log (C∞(ng/ml))at room temperature for Sevoflurane on the 
activated carbon A48 
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with the adsorbed gases at the equilibrium concentration were first removed from the bulb and 
allowed to sit in the air for 10 min to ensure any  room-temperature off-gassing was completed 
before the TGA test commenced.  This was required to ensure that desorption commenced at the 
same initial desorption temperature for all samples. As a control, the raw activated carbon 
without any adsorbed gases was tested first as a reference sample. As can be observed in Figure 
2-23, the weight (%) of the sample reduced from 100 % to approximately 91 % after 400 oC and 
there was an initial peak observed at 50 oC related to the changing weight (deriv Weght (%/oC)) 
in the sample.  This was attributed to the loss of water only from the activated carbon sample.   
 
 
TGA tests were performed with different GAC A48 samples that had been exposed to injected 
volumes of 50, 100, 150 and 200 µl Halothane, and 200 µl of isoflurane and sevoflurane. 
 As can be observed in Table 2-13 and Figures 2-24 to 2-27,  the desorption percentages were the 
same (26 %) for the 100, 150, and 200 µl of halothane injected.  For the 50 µl initial injection, 
however, the desorption percentage was only 20 %.  This was attributed to the presence of 
Figure 2-23: The raw activated A48 carbon TGA test 
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unoccupied adsorption sites in the carbon, which were all occupied at the higher injected 
volumes.  
For Isoflurane and Sevoflurane, only one TGA sample using an injected volume of 200 µl was 
analyzed. As can be observed in Figures 2-28 and 2-29, the behaviour is similar to that observed 
for the 200 µl halothane.  Therefore, it was concluded that the maximum mass of anaesthetic gas 
that could be adsorbed was equal to approximately 26 % of the initial activated carbon mass. 
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Figure 2-24: The Activated carbon A48 TGA test after adsorption in the bulb with 50 µl initial 
injected Halothane 
Figure 2-25: The Activated carbon A48 TGA test after adsorption in the bulb with 50 µl initial 
injected Halothane 
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Figure 2-27: The Activated carbon A48 TGA test after adsorption in the bulb with 200 µl initial 
injected Halothane 
Figure 2-26: The Activated carbon A48 TGA test after adsorption in the bulb with 150 µl initial 
injected Halothane 
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                                                    Table (2-13): Isotherm parameters based on Desorption 
Halothane 
Volume(µl) 
Initial Desorbent 
weight(mg) 
Total Desorption-humidity 
percentage 
Total 
desorption 
Weight(mg) 
q(mg/mg) 
Based on 
Desorption 
50 256 20 51.2 0.2 
100 258 26 67.08 0.26 
150 256.5 26 66.69 0.26 
200 258 26 67.08 0.26 
                                                            Table (2-14): Isotherm parameters based on Adsorption 
Halothane 
Volume(µl) 
C0(ng/ml) C∞(ng/ml) W(activated carbon 
weight(ng) 
q(mg/mg) Based on 
adsorption 
50 374400    
100 748800 87600 253000000 0.87106 
150 1123200 227750 257000000 0.925681 
200 1497600 546000 257000000 0.65336 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-28: The Activated carbon A48 TGA test after adsorption in the bulb with 200 µl initial 
injected Isoflurane 
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Figure 2-29: The Activated carbon A48 TGA test after adsorption in the bulb with 200 µl initial 
injected Sevoflurane 
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2-8 Continuous system 
Designing a continuous system 
 
To observe the adsorption by activated carbon in a continuous system, a specific concentration of 
anaesthetic gas, using nitrogen as the carrier gas, was passed through a column of activated 
carbon. The concentration of anaesthetic gas was measured before and after the column using the 
GC. Since only limited sources of anaesthetic gases were available, experiments were limited to 
the necessary tests that were similar to a hospital emission setting.  
The maximum adsorption capacity in a column of Activated Carbon A48 
 
Different volumes of anaesthetic gas were injected into a flask that was connected to the column 
containing adsorbent (Gac A48).  A known amount of anaesthetic gas was passed from the flask 
to the column by the carrier gas at a constant flow rate. Then, the concentration of anaesthetic 
gas, exiting the column of activated carbon, was measured during the time required to obtain the 
maximum adsorption  capacity, which  was a maximum amount of anaesthetic gas that could be 
injected into the flask without detecting any GC peak after the column. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-30: The laboratory column of activated carbon for testing 
continuous experiments 
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                                          Table (2-15): Maximum adsorption in continuous tests with different flow rates 
Flow 
Rate(ml/min) 
Maximum 
adsorption(µl ) 
Adsorbent/ 
Weight(g) 
Anaesthetic Gas 
200 900 A48/5 Halothane 
500 700 A48/5 Halothane 
700 600 A48/5 Halothane 
 
In a batch experiment, the Gac A48 adsorbed an amount of anaesthetics gas equal to 26% of its 
initial weight. In the continuous experiment, using a flow rate of 200 ml/ min, the adsorption 
weight was around 33% of the GAC weight in the column before breakthrough was detected. 
This amount decreased to 21% with an increasing flow rate up to 700 ml/min. Although the 
batch and continuous experimental conditions were not the same, these results predicted a good 
adsorbent pattern for the GAC A48 in the continuous system, which was more representative of 
the hospital emission system. 
 
 
2-9 The industrial set up 
 
A stainless steel tank with a volume of 33.98 liters containing 14.514 kg of activated carbon was 
set up at the Grand River Hospital for an industrial experiment .Emissions from the surgery 
rooms were collected and diluted with the air from the main hospital compressor .After dilution, 
the air flowed through a dryer for water removal before reaching the absorbent tank .  There are 
two tanks of adsorbent but only one of them is online at any one time. The input and output of 
the absorbent tank was connected to an FTIR for monitoring of  the composition of the combined 
anesthesia gases .  More details are shown in Figure (2-31). 
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          Figure 2-31: The overview of the Grand River Hospital Halogenated Drug Recovery System(HDR system) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
compresor 
Tank of activated carbon 
FTIR 
Dryer 
          Figure 2-32: the Grand River Hospital Halogenated Drug Recovery System (HDR system) 
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2-10 FTIR Calibration 
 
The Nicolet Avatar 360 FT-IR was purchased by Class 1 Inc. as an easy to use instrument to set 
up at the hospital to monitor, online, the composition of the combined gases, Sevoflurane, 
Isoflurane and Desflurane, in the input and output streams of the adsorbent tank. 
The first step was to calibrate this instrument for the three anesthetic gases. For calibration 
of  the instrument, a specific wave number or range of wave numbers was selected, unique to 
each of the anesthetic gases, such that the concentrations of the individual gases could be 
determined.  The selected peak or peaks should be constant for each gases at different 
concentrations. 
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 Figure 2-33: Absorbance in different wavelengths for three anesthetics in various concentrations in FTIR  
 
There were two problems in this area that needed to be resolved before confidence in the 
concentration data could be achieved . First, the high and low concentrations of the anesthetic 
gases display different profiles (refer to Figures x and x). For example, the 1 ppm isoflurane 
absorbance spectrum demonstrates a very sharp peak at 1166 cm-1 whereas at 20000 ppm,  the 
detector response in this area is saturated.  A peak at 802.28 cm-1, which was not observed to be 
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present for either the desflurane or the sevoflurane, was selected as the best substitution for 
Isoflurane at 2000 ppm.  Second,  the Desflurane peaks always overlapped with the Isoflurane or 
the Sevoflurane or both of them. 
To solve the first problem, the 5000 and 20000 ppm calibration data were  neglected as the 
typical concentration of anesthetic gases at the hospital is lower than 1000 ppm . These gases 
are  assumed to be  diluted with a high amount of air in the hospital compressor before entering 
the tank (this assumption was verified using GC analysis of  different samples  of hospital gases 
collected  in tedlar bags at different times). The 1 ppm calibration data were removed from the 
instrument set up because it could not be distinguished from background noise.   Consequently, 
the regions listed in Table (2-16) were used in the calibration method for the instrument: 
                                 Table (2-16): Selected wave number ranges and applicable concentration for each gas 
Anesthetic gas Wave number(cm-1) Concentration(ppm) 
Desflurane 1191 to 1204 10, 100, 1000 
Sevoflurane 2927 to 2950 10, 100, 1000 
Isoflurane 869.78 to 899.67 10, 100, 1000 
 
 The FT_IR measurement accuracy was assessed through the use of  GC analysis as an 
alternative method. The continuous flow of anesthetic gases passed  through the FT-IR and 
samples were collected for the GC sampling  before the input stream entered the FT-IR . The 
results are shown in Table (2-17): 
                                   Table (2-17): Comparison of FTIR and GC analysis results for each gas 
 
 
 
 
 
 
 
As can be observed in table (2-17) there was a good correlation between the GC and FT-IR 
results for Sevoflurane and Isoflurane. For Desflurane, the concentration is a little higher in the 
FT-IR, however,  that was judged to be not a significant  problem for the purpose of the 
 GC results FTIR Results 
Sample number Isoflurane  
(ppm) 
Sevoflurane  
(ppm) 
Desflurane  
(ppm) 
Isoflurane  
(ppm) 
Sevoflurane  
(ppm) 
Desflurane  
(ppm) 
1 0 201 350 35 293 462 
2 0 206 341 31.99 284 447 
3 0 197 314 39 289 422 
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industrial measurements and monitoring purpuses. 
 
2-11 Depressurizing  
 
After approximately three weeks, the tank at the hospital did not show any significant aditional 
gain in weight. Therefore, it was concluded that it had reached its maximum adsorption capacity 
and it was exchanged with the second tank. The full tank was sealed and held at its pressure (88 
Psi) during transportation to the lab. The total weight that the tank gained was 6.35 kg. In the 
first step for regeneration, it was depressurized with the known flow rates that were 
demonstrated in Table(2-18). The concentration of the desorbed anesthetic gas was measured 
using the GC . 
From 88 psi to 44 psi the concentrations of desorbed Desflurane and Sevoflurane were 
approximately constant regardless of different flow rates. Therefore , after the tank reached a 
pressure of 44 psi the depressurization was continued using a constant flow rate of 112 l/min for 
around two hours. The total weight that the tank lost due to the depressurization process was 
0.1679 g of anesthetics (0.0786 gr Desflurane+0.089 g Sevoflurane) which is very low in 
comparison with the gained weight (6.35 kg). The lost amount was estimated by multiplying the 
flow rate, time and measured concentration of anesthetics that exited from the tank. This 
experiment was repeated for this tank after a cycle of heated desorption and additional adsorption 
at the hospital. The second time the total lost weight due to the depressurization was 0.038 g  of 
anesthetics, that is approximately in the same range as the first cycle.  This suggests that the 
adsorption/desorption cycle is repeatable, and that desorption due to depressurization is a very 
minor amount. 
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                      Table (2-18): Anesthetic gas concentrations in the air exiting the tank as it was depressurized 
time(mi
n) 
GC desflurane 
concentration(ngr/ml) 
gc sevoflurane 
concentation(ng/ml) 
flow 
rate(ml/min) 
tank 
pressure(psi) 
0    88 
90 1243 1588 96.8 86 
120 1214 1581 83 84 
150 1151 1573 69 80.5 
210 1183 1577 68 80 
255 1184 1580 62 78 
300 1094 1567 58 75 
360 1109 1570 38 73 
444 1187 1579 36 70 
630 1180 1578 30 66 
720 1176 1575 27 62 
780 1162 1578 17 62 
840 1252 1591 16.8 60 
900 1261 1592 15 58 
1032 1263 1593 12 57 
1110 1283 1596 9 55 
1200 1230 1589 8 52 
1260 1245 1590 6.7 51 
1530 1313 1602 2 48 
1620 1262 1593 1.9 44 
1630 1608 1617 112 43 
1637 1501 1640 112 34 
1642 1667 1671 112 28 
1652 1899 1702 112 21 
1658 2101 1720 112 19 
1664 2245 1724 112 17 
1672 2290 1750 112 15 
1686 2459 1757 112 13 
1692 2505 1826 112 11 
1713 2408 1798 112 8 
1729 2709 1732 112 0 
 
The second time depressurizing experiment results are provided in Table (2-19): 
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Table (2-19): Anesthetic gas concentrations in the air exiting the tank as it was depressurized, after a second cycle of     
adsorption at the hospital 
Time(min) Desflurane concentration(ng/l) Sevoflurane concentration(ng/l) Isoflurane concentration(ng/l) 
2 364 510 301 
12 454 629 234 
28 269 376 182 
34 246 304 83 
45 448 537 108 
61 293 378 116 
67 332 410 104 
72 357 439 83 
77 229 288 77 
85 549 681 138 
96 229 358 90 
150 212 258 41 
170 294 387 54 
190 693 929 244 
210 504 654 148 
230 334 543 132 
250 383 487 78 
270 248 423 44 
290 365 523 112 
310 148 298 21 
330 292 348 86 
350 288 532 56 
370 230 432 48 
 
Based on the above information, the amount of anesthetic gas that was lost due to depressurizing 
is relatively low in comparison to the remaining anesthetic compounds. With regard to safety 
problems related to transportation of a pressurized tank it should be noted that if the desorption 
process takes place outside the hospital, the tank can be depressurized and transferred easily with 
losing only a very small amount of the adsorbed material. 
 
  54 
2-12 Desorption 
 
Primarily, air at the room temperature was passed through the depressurized tank to monitor the 
desorption behavior. The amount of Sevoflurane and Desflurane desorbed after 9 days is shown 
in Table 2-20: 
 
                    Table  (2-20): Desorbed anesthetics with passing air at room temperature through the tank 
D
a
y 
desorption hour 
per day 
Average Desflurane 
concentration (ng/ml) 
Average Sevoflurane 
concentration (ng/ml) 
flow rate 
(lit/min) 
total 
des 
desorbed(
g) 
total 
sevo 
desorbed(
g) 
1 5 2953 1690 10 8.859 5.07 
2 7.5 2831 1693 10 12.7395 7.6185 
3 7 2676 1696 10 11.2392 7.1232 
4 24 1712 1617 10 24.6528 23.2848 
5 24 1316 1589 10 18.9504 22.8816 
6 24 1035 1555 10 14.904 22.392 
7 24 953 1512 10 13.7232 21.7728 
8 24 836 1487 10 12.0384 21.4128 
9 24 824 1452 10 11.8656 20.9088 
 
The total desorbed anesthetic gases after 163 hour was 281.4 g of which 129 g was Desflurane 
and the remaining amount was Sevoflurane. Since the tank gained approximately 5.9 kg during 
the adsorption cycle, this suggests that a large amount of anesthetic gases still remained adsorbed 
to the carbon. This also advises that, if the desorption process was continued in the same way, it 
would take a long time to desorb all or most of the anesthetic. Thus, heating as an auxiliary 
factor was added to the desorption process.   
Adding heat to the desorption: 
 
There are two ways to add heat to the desorption process. First, the flow gas (air) can be heated 
and then passed through the tank but it was difficult to produce hot air to heat the carbon with the 
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available equipment.  Therefore, it was more effective to heat the tank directly, especially for the 
small diameter tank (24 cm diameter and 69 cm height) used in this work.  
 
 
 
 
 
 
 
 
 
 
 
 
To heat the tank, it was wrapped with an electric heating tape (the heating rate:620 Watts)and 
heated until around 111°C, as measured by a probe inserted in the middle of the tank. Since only 
a short probe was available in the lab, the temperature was measured only in the outer layer of 
the tank. This  is obviously different from the middle of the tank, which had a 26 cm diameter. In 
addition, it takes time for the heat to be conducted to the centre of tank. Thus time and position 
should be noted in the heat transfer process. The flow rate in this process was a constant amount 
of 972 ml/min.  
 
 
 
 
 
 
 
 
 
 
Figure 2-34: Absorber tank with electrical heating tape wrapped 
around for heating purpose 
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Table  (2-21): Time, temperature profile and anesthetic gas concentration in the air existing the tank during thermal 
desorption 
Time 
(min) 
temperatur
e© 
Desflurane 
Concentration(ng/ml) 
Sevoflurane 
concentration(ng/ml) 
Isoflurane 
concentration(ng/ml) 
3 22 747 1535 17 
8 22.2 820 1538 32 
15 22.4 803 1542 21 
21 29 884 1549 39 
27 47 812 1544 23 
34 66 833 1540 38 
41 80 1401 1627 67 
105 84 1504 1643 70 
112 71 1760 1681 65 
130 89 2012 1724 8 
140 95 2284 1754 103 
150 99 3500 1805 137 
166 100 4432 1941 170 
171 102 8354 2050 227 
180 105 10900 2151 551 
187 105 10474 3438 109 
208 109 20667 5227 112 
216 112 159019 32117 67 
256 112 217570 39864 98 
266 112 283910 67589 106 
300 112 262234 54923 107 
 
It was observed that it takes around 3.5 hours for the heat to penetrate in to the tank and during 
this time the desorption amount increased significantly. The concentration of Desflurane 
increased more rapidly than Sevoflurane as its boiling point(23.5°𝐶) is less than half of 
Sevoflurane (58.6°𝐶). In addition, using heat in the desorption process resulted in 351 and 44 
times faster desorption for Desflurane and Sevoflurane, respectively. 
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2-13 Condensation 
 
For recovery of anesthetic gases , a two step condensation process was designed to recover as 
much desorbed gases as possible. The melting point of Sevoflurane and Desflurane were 
reported to be -67 ° C and -101° C by Berry .[27] 
 
 
 
In the first step , water was condensed in  a flask on dry ice. In the next step, a glass coil 
immersed in dry ice (with surface temperature of -78 °C) was selected  to capture all anesthetic 
gases from the tank. The flow rate of the carrier gas was set at 1 L/min since it was observed that 
a higher flow rate resulted in water escape from the first condensation flask and blockages due to 
ice formation in the coil. It was observed that a very good condensation of the gases occurred 
from  the dry ice coil system with surface temperature of -78°C. In the flask positioned before 
the coil , a significant amount of water and a little insoluable (oily) liquid was detected .  
The input GC sampling 
The out put GC sampling 
Step 1:water condensation 
Step 2: anesthetic gas 
condensation 
Flask in dry ice 
Coil in dry ice  
Figure 2-35: The condensation system with two steps process for recovery of the anesthetics 
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After the coil, the captured liquid displayed two peaks with retention times that were 
approximately in the same region as Sevoflurane and Desflurane. Therefore, this confirmed that 
the Sevoflurane and Desflurane were recovered through the dry ice condensation process. In a 
review of historical literature, condensation with liquid oxygen at -150°C was suggested as a 
capture method. Another interesting result was that analyzing gas samples collected before and 
after the coil  with the GC illustrated an extra peak in the output gas from the coil condensation 
in the range near the Desflurane retention time. Thus , this extra peak and the oily captured 
liquid, with a density less than water (all anesthetics have density of more than water) suggested 
that degradation of these gases was occurring.  
 
                        
 
 
 
 
 
 
Figure 2-36: The captured water from the first condenser (ice) with 
oily phase visible on top 
Figure 2-37: The gas chromatography  of  the desorbed gas from the 
tank before entering the condensation part 
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 The capture efficiency in the two runs was calculated through measuring the composition of 
gases at two points (labeled in Figure (2-35) with yellow and red color): before and after the dry 
ice coil condensation. In the first run in which the whole of the coil was covered with dry ice, 
Sevoflurane  and Desflurane, the capture efficiency was 98% and 95%, respectively. In the 
second run, in which more than half of the coil was covered with dry ice , the Sevoflurane and 
desflurane capture efficiency was decreased to 96% and 68%, respectively. Therefore, the 
condensation process efficiency strongly depended on the coil length immersed in the dry ice. 
 
 
 
 
Figure 2-38: The gas chromatography of  the desorbed gas from 
the tank after leaving condensation part 
Figure 2-39: The gas chromatography of  the captured liquid that 
obtained from the coil of  dry ice(second step of condensation) 
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                                     Table (2-22): Condensed anesthetic gases amounts (calculated and measured values) 
Captured 
compound 
Density(g/ml) Average desorbed gas  
concentration(ng/ml) 
Flow 
rate(ml/min) 
Time 
(min) 
Captured 
anesthetic gas 
weight(g) 
Calculated 
products 
Sevoflurane 1.522 104926 1000 50 14.35 5.2463 
Desflurane 1.465 44811 1000 50 1.96 2.150928 
Water+ oily 
liquid 
1+less than 1 ---- 1000 50 27.777 ---- 
 
The results obtained(Table (2-22)) found that the captured liquid was more than what was 
expected. This  means that one of assumptions is not correct. The flow rate is the only factor that 
could cause this problem as the GC data was measured accurately. Measuring flow rate in 
different places of the condensation process showed that the flow rate measured after the dry ice 
coil dropped from 1000 to 333.3 L/min. Therefore a new calculation for measuring captured 
liquied is provided below in the Table (2-23). It can be observed in Table(2-23), that masses of 
4.78 g and 0.65 g of Isoflurane and Sevoflure, respectively, were obtained from the coil of dry 
ice. The calculated masses of Isoflurane and Sevoflurane determined by multiplying the flow rate 
and time with the concentrations collected by GC measurement were 5.25 g and 2.15 g . 
   Table (2-23): Condensed anesthetic gases amounts (calculated and measured values) with the correction of flow rate 
 Density(g/ml) Average desorbed gas  
concentration(ng/ml) 
Flow 
rate(ml/min) 
Time 
(min) 
Captured 
anesthetic gas 
weight(g) 
Calculated 
products(g) 
Sevoflurane 1.522 104926 333 50 4.78 5.25 
Desflurane 1.465 44811 333 50 0.65 2.15 
Water+ oily 
liquid 
1+less than 1 ---- 1000 50 27.777 ---- 
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2-14 White By-Product Sample 
 
After several days of heat addition to the desorption process, a white solid powder  was 
observed exiting the tank, which blocked the outlet tube (Figure (2-40)). Interestingly, this 
powder only accumulated outside the tank in the fitting connection and tubing when heat was 
added to the process as well. There was no sign of it inside the tank of activated carbon. In 
addition, the inside of the collection flask that captured the water from tank was appeared to be 
pitted, which could be a sign of HF (hydrofluoric acid) production . To analyze this sample, a 
series of experiments was done to discover the identity of this decomposed product: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of White By-Product Material: 
Thermogravimetric analysis was used on a sample of the white powder in an attempt to 
determine its nature and composition. Upon thermogravimetric analysis, the white powder lost 
mass from room temperature until 80C. Therefore, this product is very volatile or unstable and 
can easily transfer to the gas phase. In addition, at the end of the TGA test, nothing remained in 
the sample tray, which suggests the absence of any metal elements or presence of a strong heat 
resistance bond in the solid sample. 
Figure 2-40: Photograph of white solid material collected in the outlet tube 
(left) and condenser flask (right) after several days of thermal desorption 
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Next, solubility tests were performed to provide further information on the chemical nature of 
the White By-Product. Different polar and non polar solvents were selected to find an 
appropriate solvent to dissolve the white solid so that other  various analytical methods could be 
tested. 
                                                    Table  (2-24): Solubility of the white by-product in different solvents 
 
 
 
 
Solvent name Solubility of white 
by-product 
ether ___ 
Methanol A little 
water A little 
ethanol ___ 
Dimethylformamide (DMF) ___ 
aceton ___ 
Dicloromethane ___ 
Hexane ___ 
Benzene ___ 
Toluene ___ 
Ethyle accetate ___ 
Figure 2-41: Thermogravimetric analysis (TGA) of the White By-
Product powder 
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Sevoflurane is miscible with ethanol, ether, and benzene but the white sample did not display 
any solubility in the same solvents. Compound A, which is one reported degradation product of 
Sevoflurane, is soluble in ethyl acetate [28] but the white sample did not show the same 
behavior, suggesting it is not compound A. Therefore, analyzing this solid with Mass 
spectroscopy on a liquid sample would not be feasible. The headspace method was suggested as 
a solution but the accuracy of this method is questionable. 
All GC_MS experiment were conducted with a Varian Model CP 3800 GC and Saturn model 
2000 MS detector. As no solvent could be found for the white powder, the head space method, 
where a gas sample was collected from the top of the solid, was selected to find more 
information about this solid. The sample was pre heated in the oven before the analysis and then 
a gas sample was collected from the top of the vial which contained the white sample . Also, the 
same samples were collected from the pure Sevoflurane and Desflurane to compare results 
.There were no matches found in the library of the GC_MS device (Nist 2000) for the white 
sample mass spectroscopy. 
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                                                   Figure 2-42: The white by-products three detectable main peaks mass spectrum 
For Comparsion, mass spectra of two of the pure anesthetic compounds were determined and are 
shown in Figure (2-43) and (2-44). 
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Figure 2-43: The pure Sevoflurane mass spectrum 
Figure 2-44: The pure Desflurane mass spectrum 
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It is clear that the white by-product has different total mass and fragments from Sevoflurane and 
Desflurane. In addition, It is possible that there are some compounds in the white sample which 
do not evaporate in the head space. Therefore, they are not detected by GC_MS. 
FTIR analysis was performed on the white by-product to provide further information about the 
bands and groups present in the material. The spectrum below is the FTIR absorbance of the 
white sample at different wave lengths. The peaks from 1000-1300 cm-1 were related to C-F 
band.The peaks around 3000  cm-1  represent C-H stretch bands but the shape of them is a little 
unusul suggesting a possible different kind of band for carbon.[29] 
 
Furthermore, Nuclear Magnetic Resonace (NMR) analysis was performed to provide aditional 
information. Deuterated water was selected as a solvent for HNMR of white sample. Three 
different tests were performed to find Carbon, hydrogen (H) and Fluorine (F). In F19 decoupled 
experiments, eight numbers of  F were detected in the white sample with 2 pairs of them situated 
very close to each other. In other words, both of them would be bonded to the same carbon or 
maybe another element. There were 4 signals for hydrogen discovered with  two of them very 
near to each other. A very fast C-13 experiment exhibited only one Carbon. A more expensive 
experiment would be required detect the final number of Carbons, but this was not undertaken 
for this work.  
 
 
 
 
Figure 2-45: The white by-product FTIR spectrum 
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Figure	  2-­‐46:	  Fluorine-­‐19	  nuclear	  magnetic	  resonance	  spectrum	  of	  by-­‐product	  
Figure	  2-­‐47:	  Hydrogen	  nuclear	  magnetic	  resonance	  spectrum	  of	  by-­‐product	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Table (2-25): Summery of white by-product sample analytical tests: 
 
At this point, it was concluded that analytical analysis of this compound is difficult requiring 
more advanced instruments and time. A reference [5] was found that described the creation of 
this white powder in the Sevoflurane bottles in 1996 as a problem in Abbott company products. 
The Lewis acid degradation of Sevoflurane was explained as the reason for that event but no 
details were provided about the degradation reactions or products. In this paper, the production 
of HF and pungent odor were the same as what were observed in our experiments. Three quick 
experiments were performed to find the white sample in the degradation of Sevoflurane by 
FeCl3, FeCl3+ water and KOH. Some signs of degradation were observed such as an immiscible 
liquid by-products  but the white sample was not generated.  
 
The test name results 
TGA It is a volatile compound with no residue remaining after 80 C 
Finding Solvent Does not have same solvent as Sevoflurane or compound A . Not soluble in regular polar or 
non polar solvents except a little in water and methanol 
GC-MS Different segments and molecular weight from Sevoflurane and Desflurane. No match in 
library nist 2000 
NMR It definitely has F ,H and C elements. Possible number of eight F and four H 
Lewis acid reaction Degradation happened but no sign of white powders 
Changing copper 
connection 
The white sample amounts decreased but not disappeared 
FTIR Possible C-F and C-H band 
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As the emission system at the hospital is not an isolated process, it is possible that different 
sources of chemicals (for example from disinfection materials that are used in surgery rooms) 
can cause this degradation product. Finally, the copper fitting connections on the tank were 
changed to a stainless steel fitting, with the apparent result that a decreased quantity of white 
sample was produced. The heat in the desorption process should be controlled precisely to 
prevent the production of huge amount of this material. It was decided to continue research into 
the origins of this solid in a future project. 
 
2-15 Estimation of anesthetic gases adsorbed by the tank 
 
Three differrent ways were used to calculate the quantity of anesthetics in the tank of adsorbent 
before it reached to the saturation point at the hospital : 
Calculating the input stream anesthetic’s concentration through the FTIR  
Estimating adsorbed amounts by daily measurment of tank’s weight  
Summation of desorbed anesthetic’s values  
Unfortunately, Because of some problems in the FTIR, the data were recorded just for some days  
during the 5 weeks. Regarding the available measurements, as amounts of the consumed 
anesthetics did not demonstrate any significant change, average adsorbed anesthetics were 
assumed to be constant during a day. The results are provided in the below table: 
Figure 2-48: From left to right Sevoflurane with KOH, FeCl3 and 
FeCl3+water 
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        Table (2-26): The input stream anesthetic’s qualifications measured by the FTIR 
The name of compounds Average daily anesthetic concentration 
(ppm) 
Average  daily adsorbed anesthesia 
(g) 
Sevoflurane 589 89 
Desflurane 372 24 
Isoflurane 2 negligible 
Total anesthetics weight 808.63 115 
 
The weight of tank was measured every day through an online instrument at the hospital. The 
data are demonstrated in Table (2-27): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  71 
                                Table (2-27): Recorded weights of the tank at the hospital 
Date Average weight per day 
(lb.) 
Gained weight 
per day (lb.) 
Gained weight 
per day (g) 
07-08-2014 0.07 3.44 1560.83 
07-09-2014 3.51 0.81 365.87 
07-10-2014 4.31 0.74 333.70 
07-11-2014 5.05 0.85 384.64 
07-12-2014 5.90 0.01 2.61 
07-13-2014 5.90 -0.01 -4.17 
07-14-2014 5.89 0.38 172.26 
07-15-2014 6.27 0.46 206.70 
07-16-2014 6.73 0.20 89.09 
07-17-2014 6.93 0.40 180.63 
07-18-2014 7.32 -0.42 -191.69 
07-19-2014 6.90 -0.01 -4.29 
07-20-2014 6.89 0.01 3.41 
07-21-2014 6.90 0.40 180.41 
07-22-2014 7.30 3.05 1385.30 
07-23-2014 10.35 0.23 104.07 
07-24-2014 10.58 0.48 217.08 
07-25-2014 11.06 0.27 123.29 
07-26-2014 11.33 0.01 2.72 
07-27-2014 11.34 0.00 -1.76 
07-28-2014 11.33 0.06 25.98 
07-29-2014 11.39 0.15 68.55 
07-30-2014 11.54 0.37 168.65 
07-31-2014 11.91 0.43 195.76 
08-01-2014 12.34 0.36 162.46 
08-02-2014 12.70 -0.05 -22.50 
08-07-2014 12.65 0.00 -1.51 
08-08-2014 12.65 0.32 146.36 
08-09-2014 12.97 0.00 -1.22 
08-11-2014 12.97 -4.05 -1836.20 
 
The highlighted data in the table (2-27) are related to the weekends that the HDR system was 
automatically turned off. The total weight that was gained by the tank was 12.97 lb. (5.88 kg), at 
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which point it reached the saturation point and did not gain any additional weight. Except for the 
8th and 22th  August that show high values, the recorded weights demonstrate a decreasing 
adsorption rate especially after 3 weeks. This can be explained by the fact that after 3 weeks, the 
adsorption rate was decreased as some part of the adsorbent’s active sites were increasingly 
occupied by gas molecules. The FTIR measurements on average predicted 115 gr of anesthetics 
in the input stearm of the tank each day, that is approximately in the same range with the weight 
numbers. The strange numbers on 8th and 22th  August may relate to the water adsorption that 
was expected to be captured with a dryer in the HDR system.  
The desorption process consisted of two steps: depressurization and heated desorption. The 
depressurization and the heated desorption were explained in (2-10) and (2-11). Desorbed 
anesthetics in these two steps are organized in  the Table (2-28) : 
 
                                                Table (2-28): Desorbed anesthetic values from the tank  
The name of compunds The desorbed due to depressurizing(g) The desorbed due to heating desorption(g) 
Sevoflurane 0.020 555.4 
Desflurane 0.014 1000.8 
Total 0.214 1556.2 
 
Therefore the activated carbon A48 adsorbed the anesthetics to approximately 25% of its intial 
weight at the hospital until it reached the saturation point. This result is similar to the q 
number(26%) that was obtained in the batch laboratory experiments.  
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3.Conclusions 
In this project, an adsorption process was successfully designed and tested to capture three 
common anesthetic gases (Isoflurane, Sevoflurane and Desflurane) that vent to the environment 
through a hospital emission system. Gas chromatography with FID detection and an FTIR 
instrument were calibrated for qualification of these gases in batch and continuous experiments. 
A specific kind of activated carbon (GAC A48) with  a high capacity of adsorption was found to 
be the best adsorbent in comparison to various relevant adsorbents such as Zeolite, Silica Gel , 
Molecular Sieve 13X etc. This adsorbent demonstrated the same reversible adsorption 
characteristics for Isoflurane and Sevoflurane in the temperature range of 35-50°𝐶.The isotherm 
graphs of these two gases,as well as halothane, were determinded for the best adsorbent for room 
temperature. The Freundlich isotherm was fit to them. The Freundlich equation constants were 
discovered through finding the slope and the intercept of the plot of log q over 𝑐! . A column of 
adsorbent was used in a laboratory before setting the industrial set up to  examine all important 
factors for the continuous adsorption process. The successful laboratory results were reproduced 
in an industrial system using an appropriate tank of adsorbent. This tank, containing 14.514 kg of 
activated carbon, gained 6.35 kg weight before the saturation point for the first installation at a 
hospital emission system.  
The desorption process comprised two steps, depressurization and heated desorption. Less than 1 
% of anesthetic gases was lost from the tank in the depressurization step.The depressurization 
conditions did not have a significant effect on the desorbed amount. The heated adsorption was 
tested through warming of the column of adsorbent while air was passed through it. For a 
temperature of around 100°𝐶, the desorption concentration reached a significant amount that  
was  effectively captured in the condensation process. To prevent degradation by-products, 
higher temperatures are not recommended. 
The condensation system which consisted of a flask and a glass coil packed in dry ice effectively 
captured water and desorbed gases in two steps with an efficiency of more than 95% using a 
flow rate of approximately 1 L/min. 
The primary identification of captured liquid after the coil of dry ice by gas chromatography 
confirmed the presense of Sevoflurane and Desflurane. Significant amounts of water were 
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observed in the condensation flask that suggests an inefficiency in the water removal system in 
the hospital capture system.  
Degradation by-products in the form of a white powder and oily liquid, observed during the 
heated desorption, have completely different physical and chemical characteristics than the 
anesthetic gases. Reproduction was difficult and accurate identification of these materials was 
unsucessful using the available laboratory analytical methods. 
The resuts of these experiments demonstrated that a cost effective waste anesthetic gas 
adsorption system using activated carbon with high capacity of adsorption could be introduced 
into a hospital emission system. The recovery process using a very simple dry ice cryogenic 
condenser with high efficiency completes this reusable system.  
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3-1 Recommendations 
In order to meet expected regulations in the control of waste anesthetic gas emissions that will be 
approved in the near future in North America, it is very important to quickly develop this system 
in an industrial applicable form for installation at Hospitals. For this type of sytem, the following 
is required: 
1- Designing an online heating system to run the desorption process at a hospital 
2- Planning an appropriate heat exchanger in the desorption part to selectively condense 
desorbed gases in an economical way at a hospital. One way to improve the condensation 
process is to place two heat exchangers with different effective temperatures, one before 
the tank to better capture all water and the second one after the tank to recover anesthetics 
in the desorption stage. 
3- Using a bigger adsorbent tank to make the replacement time (3weeks) longer depending 
on  system limitations  
4- Placing some simple IR sensors (such as those used for CFC detection) instead of an 
expensive FTIR instrument in different places to make the recovery system smart in the 
detection of anesthetic gases; for example: an alarm would identify when anesthetic gases 
are detected in the output tank  stream or shut off the input stream when no gas exists 
5- Improving the system construction to prevent creating degradation products; for example, 
replacing any Lewis acid sources such as copper connections  
6- Developing the system to capture N2O in addition to other anesthetic gases  
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